Business Wire

BOEHRINGER INGELHEIM AND MIRATI THERAPEUTICS ANNOUNCE CLINICAL COLLABORATION TO STUDY BI 1701963, A SOS1::PAN-KRAS INHIBITOR IN COMBINATION WITH MRTX849, A KRAS G12C SELECTIVE INHIBITOR

Share

Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation type, and MRTX849, a KRAS G12C selective inhibitor in patients with solid tumors that harbor the KRAS G12C mutation. The collaboration will investigate the potential of this combination to provide more effective and durable responses for patients with lung and colorectal cancers who currently have limited treatment options.

Preclinical data suggest that the combination of a KRAS G12C inhibitor with a SOS1::pan-KRAS inhibitor results in increased anti-tumor activity based on the complementary mechanisms of these targeted oncology agents. By shifting the equilibrium from active KRAS(ON) towards the inactive KRAS(OFF) form, SOS1::pan-KRAS inhibitors have the potential to sensitize KRAS G12C mutant tumors to covalent KRAS G12C inhibitors that bind to KRAS(OFF).

“We look forward to collaborating with Boehringer Ingelheim to test this combination in clinical trials,” said Joseph Leveque, M.D., Executive Vice President and Chief Medical Officer of Mirati Therapeutics, Inc. “This collaboration is aligned with the broad and aggressive development strategy we have for MRTX849 and brings the potential for another therapeutic option to patients with KRAS G12C mutations.”

“We are excited to partner with Mirati in our ambition to make a difference for people living with KRAS-driven cancers. Combining our SOS1::pan-KRAS inhibitor with the mutation specific G12C inhibitor could be a win-win approach enhancing the response to therapy,” said Victoria Zazulina, M.D., Global Medical Head for Oncology at Boehringer Ingelheim. “We have a comprehensive KRAS program including the first SOS1::pan-KRAS inhibitor in the clinic, BI 1701963, for which we are exploring several combinations to optimize its therapeutic benefit in broad patient populations.”

Under the terms of the non-exclusive collaboration, Mirati will be the sponsor of the trial and Boehringer Ingelheim and Mirati will jointly share the costs of and oversee clinical development for the combined therapy.

About MRTX849

MRTX849 is an investigational, orally available small molecule that is designed to potently and selectively inhibit a form of KRAS, which harbors a substitution mutation (G12C). KRAS G12C mutations are present in approximately 14% of non-small cell lung cancer (NSCLC) adenocarcinoma patients, in 3-4% of colorectal cancer patients, and in subsets of other types of cancer. Tumors characterized by KRAS G12C mutations are commonly associated with poor prognosis and resistance to therapy, and patients with these mutations have few treatment options. MRTX849 is being evaluated in a Phase 1/2 trial treating patients with molecularly identified, KRAS G12C-positive advanced solid tumors and in the first quarter of 2020, enrollment began in the registration enabling cohort in monotherapy NSCLC, colorectal cancer and pancreatic cancer.

About BI 1701963

BI 1701963 is an investigational, orally available small molecule, that is designed to bind to the catalytic domain of SOS1 preventing the interaction with KRAS(OFF) and simultaneously blocking SOS1 driven feedback. This reduces the formation of KRAS(ON) and in consequence inhibits MAPK pathway signaling in KRAS-dependent cancers. The selective inhibition of SOS1 is a therapeutic concept that could allow KRAS blockade irrespective of KRAS mutation type (pan-KRAS approach). SOS1::KRAS inhibitors exhibit activity on a broad spectrum of KRAS alleles, including all major G12D/V/C and G13D oncoproteins, as recently published by Hofmann MH, et al. in Cancer Discovery, a journal of the American Association of Cancer Research (AACR). BI 1701963 is currently being evaluated in a Phase I clinical trial in patients with advanced KRAS-mutated cancers to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties, and preliminary efficacy of BI 1701963 alone and in combination with MEK inhibitors.

Forward Looking Statements

This press release contains forward-looking statements regarding the business of Mirati Therapeutics, Inc. (“Mirati”). Any statement describing Mirati’s goals, expectations, financial or other projections, intentions or beliefs, development plans and the commercial potential of Mirati’s drug development pipeline, including without limitation MRTX849, sitravatinib and MRTX1133, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to risks and uncertainties, particularly those challenges inherent in the process of discovering, developing and commercialization of new drug products that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.

Mirati’s forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati’s programs are described in additional detail in Mirati’s quarterly reports on Form 10-Q and annual reports on Form 10-K, which are on file with the U.S. Securities and Exchange Commission (the “SEC”) available at the SEC’s Internet site (www.sec.gov).These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

Boehringer Ingelheim’s Intended Audiences Notice

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.

Please click on the following link for ‘Notes to Editors’:

http://www.boehringer-ingelheim.com/press-release/clinicalcollaborationwithmirati

Contact information

Investor Relations and Media Contacts:

Boehringer Ingelheim
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
reinhard.malin@boehringer-ingelheim.com

Linda Ruckel
Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
linda.ruckel@boehringer-ingelheim.com

Sarah Soetbeer
Junior Product Communications Manager
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-183874
sarah.soetbeer@boehringer-ingelheim.com

 

Mirati Therapeutics, Inc.
Temre Johnson
Mirati Therapeutics Inc.
Director, Investor Relations & Corporate Communications
(858) 332-3562
ir@mirati.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Hyperconvergence & Virtualization: VMware Cloud Director Available at IKOULA28.10.2020 11:00:00 EETPress release

Nowadays virtualization and hyperconvergence are among the concerns of many companies, IKOULA – a key player in the European IaaS market - offers its customers the VMware Cloud Director solution: a stable and proven technology allowing them to easily create their private Cloud(s) and operate online their own virtual data center(s). Bringing together in a single secure environment all the storage, computing and network resources necessary for any activities, the VMware Cloud Director solution puts an end to physical infrastructures in silos, and guarantees companies an optimized use of these material resources, with a maximized ROI, controlled costs as well as the interoperability and portability of their applications between their different clouds. What are the benefits for companies using VMware Cloud Director? Simplified provisioning and consumption: users benefit from a single access point, making it very easy to provision all kinds of cloud services, but also third-party services,

Comilog Mine Taps JRC for Private LTE Network28.10.2020 10:30:00 EETPress release

Comilog, the leading manganese company, has decided to build a Private 4G/LTE network in Moanda, Gabon. JRC and Geka Telecom were selected to provide a turnkey solution. JRC will provide the LTE infrastructure for hundreds of subscribers and 4 RF sites, while GEKA Telecom will provide the full services. As part of an effort to modernize the operation process of Moanda mine, Comilog is investing in a modern and secured LTE infrastructure. Field staff will be equipped with ruggedized tablets and smartphones. The target is to digitalize the various processes to increase efficiency and reduce paper. This effort is part of an overall project called Comilog 2020 to increase the capacity of the mine and to enhance local added value. JRC LTE infrastructure was chosen for the quality of its offer. The proposed LTE infrastructure is designed to meet mission critical environment and performance. GEKA Telecom will provide its expertise for the settings of the network and the installation. “We are

NTT Com Receives “Operator Award: Embracing Cloud” at Network Transformation Awards During Layer123 World Congress 202028.10.2020 09:00:00 EETPress release

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), announced today that its recent cloud-based initiatives, including a cloud-native platform for emerging applications such as AI, IoT and 5G, received the Operator Award: Embracing Cloud from the Network Transformation Awards 20201 program at Layer1232 World Congress 2020. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006300/en/ Operator Award: Embracing Cloud (Graphic: Business Wire) NTT Com was awarded for initiatives including an edge-computing platform that will provide low latency, low cost, and guaranteeing privacy required for technologies including AI, IoT and 5G. The envisioned platform is expected to accelerate local 5G and the development of AIoT ecosystem (combination of AI and IoT) for advanced uses such as smart factories. The Network Transformation Awards recognize the

Low-Code Meets Cloud Smart: Claris Expands FileMaker Cloud to EMEA Markets28.10.2020 09:00:00 EETPress release

Claris International Inc., an Apple subsidiary and pioneering leader in low-code, today announced the official launch of FileMaker Cloud to EMEA markets. FileMaker Cloud gives EMEA businesses all of the power of the cloud - sharing, rapid deployment, scalability - without compromising on performance or losing connection to the real world of devices, sensors, even offline apps. The result is a future-proof solution that empowers businesses to rapidly create and share intelligent apps with their teams, and integrate them with other popular apps and web services. “For so many businesses, the global pandemic changed every aspect of their business overnight, which led to a massive boom in both low-code adoption and remote work technologies,” said Brad Freitag, CEO of Claris. “In many ways, Claris was built for this moment. Our commitment to low-code without limits - quickly deploying intelligent apps that both solve and evolve - means the solutions our customers build to deal with today’s c

Morinaga Milk Expands Lactoferrin Production Capacity in German Subsidiary “MILEI GmbH”28.10.2020 08:52:00 EETPress release

Morinaga Milk Industry Co., Ltd. (TOKYO: 2264) (hereafter, “Morinaga Milk”) hereby announces that its subsidiary MILEI GmbH (hereafter, “MILEI”), which has the largest share* of the global market in terms of production volume of the functional ingredient lactoferrin, will increase more than double its production capacity with the aim to enhance its lactoferrin production. * According to data for 2019 released by Absolute Reports This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027006307/en/ Powdered lactoferrin (Photo: Morinaga Milk) 1. Overview (1) Location: Kemptener Strasse 91, 88299 Leutkirch, Germany (2) Product manufactured: Lactoferrin (3) Total investment: EUR 15,000,000 (approx. JPY 1.8 billion*) * Assuming an exchange rate of 120 yen to one euro (4) Production capacity: Approx. 170 tons (more than double that of fiscal 2019) (5) Launch of operations: April 2021 (planned) 2. Background and purpose As a functional i

Wipro Strengthens Partnership With SAP on Industry Cloud Solutions for Real Estate Sector28.10.2020 08:48:00 EETPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today announced that it will co-innovate with SAP SE on cloud-based solutions for the real estate industry. Building on the Intelligent Enterprise strategy, SAP is expanding its vertical solutions to fill the whitespace in its portfolio with an ecosystem of industry cloud applications that leverage SAP® Cloud Platform with advanced technologies, and are interoperable with SAP Business Network and the intelligent suite. Partners are an integral part of SAP’s Intelligent Enterprise strategy and Wipro is contributing their industry insights and knowledge in the development of purpose-built solutions for the real estate industry. To start with, Wipro has launched the Tenant Acquisition Management (TAM) solution for the real estate industry. Anchored with intelligent technologies like robotic process automation, artificial intelligence and machine le

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom